Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Sector: Pharmaceutical Preparations
Industry: Medical - Pharmaceuticals
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 445.28M shares outstanding
USRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
The company was founded in 1996 and is based in New York, New York.
Arthur McGivern
Executive Vice President, Investments & General Counsel
Bonnie Bassler
Bonnie Bassler, Ph.D.
Director
Carole Ho
Employees
100
Country
US
Sector
Healthcare
Website
royaltypharma.com
Loading congressional disclosures…
based on 445.28M shares outstanding
US30d Avg
2.97M
60d Avg
2.94M
90d Avg
2.94M
